Desentum is a clinical-stage, research-oriented biopharmaceutical company specialized in developing novel types of allergy immunotherapy products (aka allergy vaccines) that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. We have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of vaccines against common types of allergies.
Our goal is to provide long-term relief from allergic symptoms with only a few months of treatment, as well as reduce the social and economic burden allergies cause to both individuals and society.
Company Details
- Employees
- 12
- Founded
- 2011
- Address
- Kivipylväänkuja, Espoo,southern Finland 02940,finland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- desentum.com
- Keywords
- immunotherapy and allergy vaccines.
- HQ
- Espoo, Southern Finland
Desentum Oy Questions
Desentum Oy's website is desentum.com
Desentum Oy's LinkedIn profile is https://fi.linkedin.com/company/desentum-oy
Desentum Oy has
12 employees.
View email and phone details for 12
employees at Desentum Oy.
Desentum Oy's industry is
Pharmaceutical Manufacturing
Desentum Oy's top competitors are
Valo Therapeutics Ltd,
Enifer,
Tilt Biotherapeutics Ltd,
Solar Foods,
Medix Biochemica,
Iceye,
Infinited Fiber Company,
Herantis Pharma Plc.,
Aimmune Therapeutics,
Dbv Technologies.
Desentum Oy's categories are Pharmaceutical Manufacturing
Desentum Oy's founding year is 2011
